Literature DB >> 29694253

Serum levels of proinflammatory, anti-inflammatory cytokines, and RANKL/OPG in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.

Shuo Zhang1, Chen Li2, Siya Zhang3, Li Li4, Weihong Zhang5, Zhenhua Dong2, Wen Zhang1.   

Abstract

OBJECTIVE: To measure the expression of proinflammatory, anti-inflammatory cytokines, and receptor activator NK-κB ligand (RANKL)/osteoprotegerin (OPG) in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, and to assess the relationship between those factors and disease activity.
METHODS: We studied 30 cases of SAPHO syndrome and 15 healthy controls. According to the Visual Analogue Scale (VAS) pain scores and Bath Ankylosing Spondylitis Activity Index (BASDAI), patients were divided into active group and stable group. The serum levels of IFN-γ, TNF-α, TGF-β1, IL-1β, IL-4, IL-6, IL-8, IL-17A, IL-22, RANKL, and OPG were determined by ELISA.
RESULTS: The active group IL-6 (2.34 ± 1.31 pg/ml), IL-8 (36.41 ± 12.93 pg/ml), and IL-17A (29.17 ± 4.01 pg/ml) levels were significantly higher than those in the stable group (p < .01) and healthy controls (p < .01). RANKL in active group (73.43 ± 57.07 pg/ml) was significantly higher than the ones in other groups (p < .0001), with increased RANKL/OPG ratio in the active group compared with other groups (p < .05). While the level of TGF-β1 in the active group was significantly lower than that in the stable and control groups (p < .0001). There was no significant difference with clinical significance were found in IFN-γ, TNF-α, IL-1β, IL-4, IL-22, and OPG.
CONCLUSION: In active SAPHO patients, there was an anomaly of proinflammatory and anti-inflammatory cytokines balance in SAPHO syndrome.

Entities:  

Keywords:  RANKL/OPG; SAPHO syndrome; T cells; cytokines; inflammation

Mesh:

Substances:

Year:  2018        PMID: 29694253     DOI: 10.1080/14397595.2018.1469580

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  8 in total

1.  A retrospective study of bone scintigraphy in the follow-up of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: is it useful to repeat bone scintigraphy for disease assessment?

Authors:  Chen Li; Lun Wang; Nan Wu; Yihan Cao; Xiaochuan Sun; Wen Zhang; Hongli Jing
Journal:  Clin Rheumatol       Date:  2019-12-19       Impact factor: 2.980

2.  Enhanced migration and adhesion of peripheral blood neutrophils from SAPHO patients revealed by RNA-Seq.

Authors:  Yuxiu Sun; Chen Li; Mengmeng Zhu; Shen Zhang; Yihan Cao; Qiao Yang; Pengfei Zhao; Guangrui Huang; Anlong Xu
Journal:  Orphanet J Rare Dis       Date:  2019-08-08       Impact factor: 4.123

3.  Genome-Wide Association Identifies Risk Pathways for SAPHO Syndrome.

Authors:  Ruikun Cai; Yichao Dong; Mingxia Fang; Yuxuan Fan; Zian Cheng; Yue Zhou; Jianen Gao; Feifei Han; Changlong Guo; Xu Ma
Journal:  Front Cell Dev Biol       Date:  2021-03-18

4.  Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome of femoral neoplasm-like onset: a case-based review.

Authors:  Cheng Qiu; Lin Cheng; Haodong Hou; Tianyi Liu; Bohan Xu; Xing Xiao; Zhankui Wang; Qing Wang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

Review 5.  New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors:  Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal:  J Inflamm Res       Date:  2022-04-13

Review 6.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

7.  Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab).

Authors:  Akshay Flora; Richard Holland; Annika Smith; John W Frew
Journal:  JAAD Case Rep       Date:  2021-06-06

8.  Rapid induction of clinical remission in SAPHO syndrome using high-dose Tripterygium glycosides: A case report.

Authors:  Liang Gong; Lun Wang; Yihan Cao; Chen Li
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.